Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
After a conference lacking the wow factor, biotech winners and losers emerge.
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?